IL-6 (Siltuximab Biosimilar) Human mAb was confirmed to bind to its intended target protein IL-6 using bio-layer interferometry.

IL-6 (Siltuximab Biosimilar) Human mAb is produced at Cell Signaling Technology. Siltuximabb is an antibody directed against human IL-6.

IL-6 (Siltuximab Biosimilar) Human mAb is a biosimilar antibody for Siltuximab. Siltuximab is an FDA-approved human monoclonal antibody directed against IL-6. Siltuximab may help reduce inflammation and stop the growth of cancer cells or abnormal blood cells.

Interleukin-6 (IL-6) is a pleiotropic cytokine with central roles in immune regulation, inflammation, hematopoiesis, and oncogenesis. Its biological activities are shared by other IL-6 family members, such as leukemia inhibitory factor and oncostatin M (1). To exert its biological effects, IL-6 must bind to the IL-6 receptor (IL-6R), composed of two alpha chains (IL-6Rα, 80 kDa) and two beta chains (IL-6Rβ or gp130, 130 kDa). Two moieties of IL-6 and two pairs of these receptor chains form a functional hexameric IL-6R complex. The subsequent intracellular signaling events are activated via gp130, which is the common signal transducer of cytokines related to IL-6. Activation of the IL-6R stimulates at least three major signaling pathways: JAK/STAT, PI-3 kinase, and MAPK signaling pathways (2,3).